bioMerieux (OTCMKTS:BMXMF) Given Consensus Recommendation of “Reduce” by Analysts

bioMerieux (OTCMKTS:BMXMF) has earned an average recommendation of “Reduce” from the six brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a hold recommendation on the company.

BMXMF has been the subject of several research reports. Piper Sandler initiated coverage on shares of bioMerieux in a research note on Thursday, June 11th. They set a “neutral” rating for the company. Zacks Research upgraded shares of bioMerieux to a “hold” rating in a research note on Tuesday, April 28th. Morgan Stanley cut shares of bioMerieux from an “overweight” rating to an “underweight” rating in a research report on Tuesday. UBS Group cut shares of bioMerieux from a “buy” rating to a “neutral” rating in a research report on Monday, June 1st. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th.

bioMerieux Price Performance

bioMerieux stock opened at $78.00 on Tuesday. bioMerieux has a 1 year low of $77.00 and a 1 year high of $152.00. The firm has a 50 day moving average price of $87.83 and a 200 day moving average price of $107.46. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.48 and a current ratio of 2.39.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.